[ad_1]
The ones at the forefront of the US and Europe are now in so-called phase three studies, and after that they basically just wait for the approval of the US and European authorities.
Of course, this is good news for the world’s population, but also for company owners: Stock prices have generally risen during the fall and have been driven by information that several of the candidate vaccines appear be very effective and without major side effects.
The US-German collaboration Pfizer / Biontech is one of the players that is at the forefront of developing a vaccine, and one of the players that may reach Swedish health centers and hospitals next year.
The Swedish government announced on Tuesday a joint EU purchase has secured 4.5 million doses of its vaccine provided it is approved. The first doses are believed to be able to reach risk groups and care workers in Sweden as early as the first half of 2021.
American Pfizer is one of the world’s largest pharmaceutical companies with a market capitalization of more than $ 200 billion, slightly less than it was at the beginning of the year. Partner Biontech, meanwhile, has made a remarkable stock market journey thanks to the development of the vaccine. In total this year, the company’s market capitalization has increased by more than 150 percent to just over $ 20 billion.
The successes have also spread. When they announced early last week that the vaccine appears to provide more than 90% protection, they themselves rose dramatically in the news, but there was also a sigh of relief in the markets that sent prices skyrocketing. Not least among airlines.
“It was a wonderful moment because we weren’t expecting such a high degree of efficiency,” Biontech founder Ugur Sahin said in an interview with US CNBC in connection with the announcement.
The founder of Biontech, Ugur Sahin.
Photo: Biontech
Biontech is a relatively young pharmaceutical company, founded in 2008 by the research couple Ugur Sahin and Özlem Tureci in Mainz, Germany. The primary focus from the beginning has been individualized cancer treatment and the goal is to become a world leader in that field. But with the experience available, opportunities have also been seen in other areas.
The company was listed on the stock exchange last fall and has since seen its share price grow by more than 300 percent.
They already have collaborated with Pfizer on the flu vaccine, and in March of this year, the two decided to expand the collaboration to also fight the coronavirus. And it seems to be doing well considering what the company communicated last week.
“This could be the beginning of the end of the covid era,” Ugur Sahin said in several interviews after the 90 percent efficiency announcement.
On Wednesday, the efficiency rose further, to 95 percent, and Pfizer CEO Albert Bourla said no serious side effects were seen in the tests.
“The results of the study mark an important step in the historic eight-month journey toward a vaccine that can help stop the devastating pandemic,” he said in a statement according to the New York Times.
Albert Bourla, CEO of Pfizer,
Photo: Pablo Martinez Monsivais
That degree of efficiency is in line with the American competitor Moderna, which reported an efficiency of 94.5 percent.
Unlike Pfizer and Biontech Moderna’s vaccine, on the other hand, does not need to be stored at minus 70 degrees, but can be stored in the refrigerator. This is a great advantage because it broadens the potential user base.
The modern vaccine is in phase three, when it is tested in large numbers of people. Mothers’ management hopes to have 20 million doses ready by December, provided the US Food and Drug Administration approves.
The stock price took a big step when the stock market opened on Monday after they reported their results. From trading at about $ 90 a share on Friday, it rose to just over $ 99 after Monday’s announcement of near 95 percent efficiency. Since then, it has backtracked a bit when investors have made a profit.
Modern Stock Price During Fall It is spectacular and shows the high hopes that there is for an effective vaccine that can lead to mass vaccination next year to stop Covid-19. As recently as the end of October, the price was below $ 29.
It is a relatively new company that was founded in 2010 and four years later the company went on to create vaccines with the new technology.
Moderna has collaborated with Swedish-British AstraZeneca since 2013 and since 2016, AstraZeneca is a major player in Moderna. However, so far no information about his vaccine has reached Sweden.
Astra Zeneca, one of the companies in the fight for vaccines.
Photo: Jonas Lindstedt
Swedish-British AstraZeneca, on the other hand, has already agreed to delivery to Sweden. They are developing a vaccine in collaboration with a research team at the University of Oxford. Since the beginning of October, the European Medicines Agency (EMA) has carried out a “continuous review” of the vaccine. This means that the authority reviews AstraZeneca research data as it is received, rather than waiting for all results, to speed up the process to approval.
Unlike Moderna, AstraZeneca and the Oxford University candidate vaccine is based on traditional vaccine manufacturing. The vaccine is in the final phase of phase 3 testing. In early November, the company’s CEO, Pascal Soriot, said in an interview with DN that “when we’re done, we can start vaccinating people in January, possibly late December. “
Pascal Soriot, Swedish-British CEO of Astra Zeneca.
Photo: Tom Stockill
The share price, on the other hand, hasUnlike Modernas, it has not experienced any spectacular rebound. During the year, he has run more of a roller coaster. In the US market, the price has gone from just under $ 50 at the end of October to a high of $ 58 on November 11. After that, it has regressed a bit.
The third player Sweden can receive vaccines from is Johnson & Johnson. There is also an American company that has reached an agreement with the EU, through which Sweden can participate in the vaccine. In total, there are up to 400 million doses in the EU, of which 4.5 million in Sweden.
Its shareholders haven’t seen the same sharp increases as some of its competitors. The annual price has risen only a small percentage. But developing its vaccine has not been easy either.
In mid-October, the share price fell. abruptly when one was forced to interrupt phase three tests after one of the test subjects fell ill. Only after two weeks, when an independent committee examined the case, could testing be resumed.
“Based on the information collected so far and the statements of independent experts, the company has not found any evidence that the candidate vaccine was behind it,” the company said in a statement at the time.
The company expects the vaccine to be ready for approval and use in early 2021, if it proves safe and effective, according to a press release.
